There has been a growing interest in developing methodologies for the delivery of bioactive compounds (drugs) to specific physiological targets. The advantage of using light to release a caged molecule is that this provides precise control over the time, location, and concentration of such delivery. Nitric oxide is a small molecule bioregulator that is a powerful vasodilator as well as being an effective radiation sensitizer that may have potential applications in the radio-therapy of tumors. This presentation will focus on ruthenium centered PhotoNORMs (Photoactive Nitric Oxide Releasing Molecules) with salen (N,N'-bis(salicylidene)ethylenediamine) and salophen (N,N'-bis(salicylidene)phenylenediamine) ligands. Several ligand scaffolds have been synthesized with varying solubility, optical properties and quantum yields while retaining water, oxygen, and thermally stability. Quantum yield measurements have been performed to determine NO production using a Sievers Nitric Oxide Analyzer to observe the nitric oxide photoproduct in real time upon irradiation. Incubation of one such PhotoNORM with human melanoma B16F10 cells displayed no toxicity in the absence of irradiation, further displaying the ability of photochemistry as a milder alternative to regular chemotherapeutic approaches. We will discuss the uses of such ruthenium nitrosyl compounds, their quantum yield release of nitric oxide and their insertion into secondary structures for drug delivery.

Release of nitric oxide from ruthenium centered PhotoNORMs and their use as small molecule delivery platforms

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.